Equity
€69,569 ▲ 86.8%
API PHARMA paid out €833 in dividends. That is 3% of the 2025 profit.
API PHARMA
Overview
Lifetime
3 annual accounts with figures on one time axispeak €52,678 (2025)
€52,678▲ 5.1%
peak €34,976 (2024)
€33,164▼ 5.2%
peak €69,569 (2025)
€69,569▲ 86.8%
€46,890▲ 6.4%
Board1 name since 2023
1 director
Documentsfilings and deeds
06-07-202625 days before the deadline
2025micro format
Dividend €833Equity from €37,239 to €69,569Cash from €46,660 to €90,141
Key points
from the 2025 annual accountsTurnover
≈ €250,000 estimated
The micro format states no turnover.
Liquidity
2.40 was 1.76 in 2024
Short-term debts rose from €32,658 to €42,243.
Starting capital
€2,000
At the same address
9 companies
Position in the sector
€33,164
Higher net result than 81% of companies in retail trade. Sector median €4,763 · 25,208 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 39,274 companies had the same profile as API PHARMA has now. Each dot stands for 99 companies, two years later.
95.8%
were still trading
2.3%
stopped another way
1.8%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,274 companies, not a prediction for API PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered office moved from Tilff to LIEGE Boulevard Frère Orban
New registered office: 34/5b, 4000 LIEGE Boulevard Frère Orban · Previous registered office: 4130 TILFF (Esneux) -Rue de la Charrette 30 · Board meeting of 03-03-2026 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0805949739
Incorporation
Founding capital of €2,000, 100 shares · Founder: · Appointment: (director) · published on 20-09-2023 · Gazette deed
First establishment
Boulevard Frère-Orban 34, Liège
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| API PHARMA Liège | €116,460 | €52,678 | 59.7% | - |
| NOVAPLEX Modave | €119,122 | €52,898 | 77.1% | - |
| Farma Jana Lo-Reninge | €118,424 | €57,937 | 80.1% | - |
| KARBON PLUS Diksmuide | €127,790 | €52,214 | 80.4% | - |
| Bartholomees Evaline Pelt | €120,179 | €52,717 | 92.9% | - |
| O.Sabur Genk | €129,423 | €57,943 | 57.1% | - |
| MONTPHARMA Forest | €135,487 | €55,087 | 82.3% | - |
These companies have the same main activity as API PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €118,000 and €135,000, founded between 2023 and 2024.
Official details
Source: KBO- Status
- Active since 18-09-2023Normal situation
- Registered office
- 11 active companies are registered at this address1 started in the 12 months before. Source: KBO register, as of 12 November 2026.
- Activity
- Retail sale of pharmaceutical productsNACE 47730and 4 others
- Establishment unit
- 2.350.465.9904000 Liège, since 18-09-2023
- Financial year end
- 31 December
- Peppol
- Reachable since 23-10-2025
Annual accounts 2025
- €52,678▲ 5.1%
- €33,164▼ 5.2%
- €69,569▲ 86.8%
- €116,460▲ 43.3%
- Filing
- Filed on 06-07-2026, 25 days before the end of the filing period
Insights on API PHARMA
API PHARMA files the micro format. That format states no turnover. The gross margin rose from €3,020 in 2023 to €52,678 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette.
Financials
Annual accounts 2025
micro format, filed on 06-07-2026, 25 days before the deadline€52,678
▲ 5.1%
€43,660
▼ 3.2%
€33,164
▼ 5.2%
€59,180
▲ 137%
59.7%
▲ 13.9 percentage points
2.40
▲ 0.64
Turnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.
Turnover ≈ €250,000. Estimated: probably between €140,000 and €340,000.
Balance sheet
balance sheet total €116,460 on 31-12-2025What the company ownsHow it is paid for
in euro
in euro
Position in the sector
59.7%
Higher than 72% of 25,237 companies in 2025.
2.40
Higher than 70% of 24,245 companies in 2025.
28.5%
Higher than 91% of 24,434 companies in 2025.
API PHARMA
Middle half of the sector
80% of the sector
Micro accounts in retail trade (NACE 47)
Net result: top quarter · Equity: middle half · Balance sheet total: middle half · Working capital: middle half
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Balance sheet: assets | ||||
20/58 |
116,460 | 81,294 | 23,346 | |
21/28 |
15,037 | 23,689 | - | |
22/27 |
15,037 | 23,689 | - | |
24 |
15,037 | 23,689 | - | |
29/58 |
101,423 | 57,606 | 23,346 | |
40/41 |
10,992 | 10,945 | 8,083 | |
40 |
10,992 | 10,945 | 8,083 | |
54/58 |
90,141 | 46,660 | 14,879 | |
490/1 |
290 | - | 384 | |
| Balance sheet: equity and liabilities | ||||
10/49 |
116,460 | 81,294 | 23,346 | |
10/15 |
69,569 | 37,239 | 3,122 | |
10/11 |
2,000 | 2,000 | 2,000 | |
14 |
67,569 | 35,239 | 1,122 | |
17/49 |
46,890 | 44,056 | 20,224 | |
17 |
4,648 | 11,397 | - | |
170/4 |
4,648 | 11,397 | - | |
42/48 |
42,243 | 32,658 | 20,224 | |
42 |
6,750 | 6,493 | - | |
44 |
493 | 1,761 | 1,415 | |
440/4 |
493 | 1,761 | 1,415 | |
45 |
27,605 | 17,551 | 8,226 | |
450/3 |
26,005 | 15,951 | 5,476 | |
454/9 |
1,600 | 1,600 | 2,750 | |
47/48 |
7,395 | 6,852 | 10,583 | |
| Income statement | ||||
9900 |
52,678 | 50,122 | 3,020 | |
630 |
8,652 | 2,269 | - | |
640/8 |
365 | 2,726 | 321 | |
9901 |
43,660 | 45,127 | 2,699 | |
65/66B |
709 | 278 | 9 | |
65 |
709 | 278 | 9 | |
9903 |
42,951 | 44,849 | 2,690 | |
67/77 |
9,788 | 9,873 | 735 | |
9904 |
33,164 | 34,976 | 1,955 | |
9905 |
33,164 | 34,976 | 1,955 | |
| Appropriation of the result | ||||
9906 |
68,402 | 36,098 | 1,955 | |
14P |
35,239 | 1,122 | - | |
694/7 |
833 | 859 | 833 | |
694 |
833 | 859 | 833 | |
| Document | ||||
The notes to these accounts have 5 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 06-07-2026.
Filings
each dot is a set of accounts, on the day it reached the National BankKey figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| 52,312 | 47,396 | - | ||
| 41,815 | 37,245 | - | ||
| 0 | 25,958 | - | ||
| 43,480 | 31,782 | - | ||
| 59,180 | 24,947 | 3,122 | ||
| 59.7% | 45.8% | 13.4% | ||
| 2.40 | 1.76 | 1.15 | ||
| 0.67 | 1.18 | 6.48 | ||
| 47.7% | 93.9% | 62.6% | ||
| 28.5% | 43.0% | 8.4% | ||
| 73.80 | over 100 | - |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Investments
fixed assets acquired| Item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Tangible fixed assets | - | €25,958 | - |
| €8,652 | €2,269 | - |
Source: notes to the 2023 to 2025 annual accounts (statement of fixed assets)
Insights on API PHARMA
The operating result for 2025 is 3% lower than in 2024.
Debt's share of the balance-sheet total falls from 54.2% to 40.3%. Equity and debt are higher.
Board & ownership
Board
1 director, since incorporationDirector (not named in the articles)
since 14-09-2023
term without a fixed end
listed in the 2025 annual accounts, filed on 06-07-2026
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- “Article 11. Pouvoirs de l’organe d’administration S’il n’y a qu’un seul administrateur, la totalité des pouvoirs d’administration lui est…”deed of 20-09-2023
Mandates through the years
1 name, the dashed line is todayDirector (not named in the articles)
Board
Mandates as a list
-
- Director (not named in the articles), from 14-09-2023 to date
Control
Founder
This company
API PHARMA
Equity €69,569
Profit €33,164 in 2025
Capital
- Contribution
- €2,000
- Shares
- 100
- Contribution per share
- €20
- Equity per share
- €696 in 2025
- Source
- deed of 20-09-2023
Articles of association
deed of 20-09-2023 (in French)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- “Fixe ou proportionnelle, assemblée générale”
- Kind of sharesThe articles set which classes of shares exist and what rights each class carries.
- 100 shares
- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- “Sans recours, actionnaire voulant céder tout ou partie peut exiger des opposants rachat à valeur fixée à dires d’expert choisi de commun…”
- Statutory auditorA statutory auditor is a registered auditor who checks the annual accounts. Small companies need not have one. According to the deed, the legal criteria do not require one here.
- No statutory auditor
Shareholders
At incorporation
deed of 20-09-2023 ↗
- 100 shares (100%) · €2,000 in cash
Capital transactions
Capital over time
- 20-09-2023 Incorporation · €2,000
- 20-09-2023 Incorporation · €2,000 · 100 shares
Network & group
No group
API PHARMA has no parent and no holdings in its annual accounts. is the only director. API PHARMA shares no director with another company.
At the same address
Boulevard Frère Orban 34, 4000 Liège · 10 other companies| SAGESTI
registered office since 14-08-2025 · founded in 2025 |
total assets €206,376 (2025) 1026.506.062 |
| LPORL
registered office since 12-12-2024 · founded in 2024 |
total assets €66,802 (2025) 1017.265.130 |
| EP Legal
registered office since 22-04-2026 |
founded in 2026 1037.178.933 |
| NATAN VISION
establishment since 01-01-2011 |
founded in 2011 0833.508.528 |
| Association des Copropriétaires Résidence Montesquieu à Liège Boulevard Frère Orban 34 - 35
registered office since 01-01-2008 |
founded in 1968 0850.143.929 |
| PATRIMOINE SAINTE - ODILE
registered office since 30-08-2006 |
founded in 2006 0883.225.085 |
| COMMANDERIE DES ANYSETIERS DE LA PRINCIPAUTE DE LIEGE
registered office since 17-01-2004 |
founded in 2004 0866.140.318 |
| Liénard, Alain (sole trader)
establishment since 01-10-1989 |
founded in 1989 0813.076.170 |
| Cops, Astrid (sole trader)
establishment since 02-01-1984 |
founded in 1984 0854.490.420 |
| Brundseaux, Guy (sole trader)
establishment since 01-10-1975 |
founded in 1975 0856.855.636 |
Timeline
Timeline
8 events since 2023Filings
Financial
Establishments
Address
2023202420252026
Deadline for the 2026 accounts: 31-07-2027
2026
Annual accounts 2025 filed NBBmicro format · 25 days before the deadline
Registered office moved from Tilff to LIEGE Boulevard Frère OrbanNew registered office: 34/5b, 4000 LIEGE Boulevard Frère Orban · Previous registered office: 4130 TILFF (Esneux) -Rue de la Charrette 30 · Board meeting of 03-03-20262 points ▸
- Board meeting, 03-03-2026
- Registered-office move, 34/5b, 4000 LIEGE Boulevard Frère Orban
2025
Registered in the Peppol Directory Reachable for e-invoices through 0208:0805949739
Annual accounts 2024 filed PDFmicro format · 23 days before the deadline
2024
Highest result from 2023 to 2025 net €34,976 ▲1,689% The operating result of €45,127 and the net result of €34,976 are both a record.
Annual accounts 2023 filed PDFmicro format · 22 days before the deadline
2023
IncorporationFounding capital of €2,000, 100 shares · Founder: · Appointment: (director) · published on 20-09-20236 points ▸
- Registered office clause, rue de la Charrette 30, 4130 Esneux (Tilff)
- Director appointment, (director (not named in the articles))
- Permanent representative,
- Founder,
- Founding capital, €2,000
- Founding capital, €2,000, 100 shares
- The deed holds 6 more points.
First establishment Boulevard Frère-Orban 34, Liège
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
On 18 September 2023, API PHARMA was incorporated as a private limited company by one natural person, with a starting capital of €2,000.12 In 2026 the registered office moved to LIEGE Boulevard Frère Orban.3 has served as director since 2023.4 Total assets went from €23,346 in 2023 to €116,460 in 2025.5
Company details
Identity
- Enterprise number
- 0805.949.739
- VAT number
- BE 0805.949.739
- Peppol ID
- 0208:0805949739
- Legal form
- Private limited company
- Status
- Active, normal situation
- Founded
- 18-09-2023
- Financial year
- ends on 31 December
- Peppol
- Reachable since 23-10-2025Follow this company and you will hear the next morning if it leaves the Peppol register.
- Name
- API PHARMA in French
- Entity type
- Legal entity
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimiteddeed of 20-09-2023 (in French)
Activities
NACEBEL 202547730
Retail sale of pharmaceutical products main activity
85592
Vocational training
85599
Other education
Codes under NACEBEL 2008
47730
Retail trade main activity
70210
Activities of head offices; management consultancy activities
70220
Business consulting
85592
Vocational training
85599
Other education
- PurposeThe purpose describes the activities the company may carry out under its articles.
- “Toutes opérations et activités se rattachant directement ou indirectement aux activités suivantes : l'achat, la vente, la prise en location…”deed of 20-09-2023 (in French)
13 activities
- Toutes opérations et activités se rattachant directement ou indirectement aux activités suivantes : l'achat, la vente, la prise en location, l'exploitation sous quelque forme que ce soit, et la location d'officines pharmaceutiques.
- La formation et l'organisation de cours en toutes matières relatives à la pharmacie.
- La vente en gros ou au détail de tous produits se rapportant ou non à ces activités.
- L'activité d'import-export de tous produits se rapportant ou non à ces activités.
- Le conseil dans les domaines pharmaceutique, scientifique, technique, alimentaire, au sens large du terme.
- La recherche et développement, la promotion, l'achat et la vente de tous produits médicaux, pharmaceutiques, thérapeutiques, cosmétiques, diététiques, à usage humain, végétal, animal, biologiques, produits chimiques, de tous matériels et instruments médicaux et chirurgicaux.
- La société peut rendre des services de soutien à des tiers et en particulier, à des sociétés liées.
- De manière générale, la société peut, sans que cette énumération soit limitative, acquérir, aliéner, prendre ou donner en location tous immeubles ou fonds de commerce, acquérir, créer tous brevets, licences, marques de fabrique ou de commerce, s'intéresser de toutes les manières, sous toutes les formes et en tous lieux, dans toutes sociétés ou entreprises, affaires, associations, institutions dont l'objet serait similaire, analogue ou connexe au sien, ou simplement utile à l'extension de ses opérations ou d la réalisation de tout ou partie de son objet.
- Dans le cadre de la réalisation des objets qui précèdent, la société peut également prêter de l'argent, à intérêts ou non, donner caution tant pour ses propres engagements que pour les engagements de tiers, entre autres en donnant ses biens en hypothèque ou en gage, y compris son propre fonds de commerce.
- Elle peut faire, en Belgique et à l'étranger, d'une façon générale, toutes opérations commerciales, industrielles, financières, mobilières ou immobilières, se rapportant directement ou indirectement à son objet ou pouvant le favoriser.
- Elle peut effectuer tous placements en valeurs mobilières et immobilières et les gérer, s'intéresser par voie d'association, d'apport ou de fusion, de souscription, de participation, d'intervention financière ou de toutes autres manières, dans toutes sociétés, associations ou entreprises, existantes ou à créer, et conférer toutes sûretés pour comptes de tiers.
- La société peut être administrateur, ou liquidateur d'autres sociétés ou entreprises.
- Au cas où la prestation de certains actes serait soumise à des conditions préalables d'accès à la profession, la société subordonnera son action, en ce qui concerne la prestation de ces actes, à la réalisation de ces conditions.
Registered office and establishments
1 establishment| Establishment | Since | Unit number |
|---|---|---|
| Boulevard Frère-Orban 34 registered office 4000 Liège | 18-09-2023 | 2.350.465.990 |
1 former office
- 4130 TILFF (Esneux)-Rue de la Charrette until 03-03-2026 · deed of 25-03-2026
Buildings and parcels at the address
- Ground area
- 420 m²
- Buildings
- 388 m²
- Volume, LiDAR
- 12,552 m³
- Tallest building
- 36.0 m
Buildings to scale, each on its own parcel
Parcels
| Cadastral parcel | Area | Buildings | Height / floors |
|---|---|---|---|
| 62805B0476/00R024 | 420 m² | 1 · 388 m² | 36.0 m · 11 |